Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Modulating the cold tumor microenvironment.
Journal: Med (New York, N.Y.)
Published: October 24, 2024
Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By Tissue-Specific Suppression of SLAMF6 Signaling.
Journal: bioRxiv : the preprint server for biology
Published: May 15, 2024
Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment.
Journal: The Journal of experimental medicine
Published: January 07, 2024
TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer.
Journal: Nature immunology
Published: June 30, 2022
Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms.
Journal: Molecular cancer therapeutics
Published: February 23, 2022
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
Journal: Cancer cell
Published: December 16, 2021
Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 25, 2020
Harnessing Natural Killer Cell Function for Genitourinary Cancers.
Journal: The Urologic clinics of North America
Published: October 03, 2020
Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
Journal: Urologic oncology
Published: June 02, 2020
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.
Journal: Urologic oncology
Published: December 10, 2019
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
Journal: European urology
Published: April 11, 2019
Last Updated: 09/26/2026